Clinical Scorecard: Oncologists' Understanding, Perspectives, and Approaches to Chemotherapy Resistance: Findings from an International Cross-Sectional Analysis
At a Glance
Category
Detail
Condition
Chemotherapy Resistance
Key Mechanisms
Drug efflux, DNA damage repair, inhibition of cell death, epithelial-mesenchymal transition, maintenance of cancer stem cells.
Target Population
Oncologists across multiple countries
Care Setting
Public and private hospitals, specialized cancer treatment centers, academic institutions
Key Highlights
3,779 oncologists participated in the study.
Female oncologists showed higher odds of good knowledge and positive attitudes.
Post-doctorate holders had greater odds of good knowledge and positive attitudes.
Longer professional experience and exposure to chemotherapy resistance cases were associated with better knowledge.
Guideline-Based Recommendations
Diagnosis
Assess oncologists' understanding of chemotherapy resistance mechanisms.
Management
Implement targeted educational programs to improve management of chemotherapy resistance.
Monitoring & Follow-up
Evaluate the impact of oncologists' knowledge on patient outcomes.
Risks
Recognize that chemotherapy resistance can lead to disease progression and reduced quality of life.
Patient & Prescribing Data
Cancer patients receiving chemotherapy
Resistance can necessitate more aggressive and toxic therapies.
Clinical Best Practices
Encourage continuous professional development for oncologists.
Tailor cancer treatment based on tumor characteristics and resistance likelihood.
by Bassam Abdul Rasool Hassan, Ali Haider Mohammed, Khalis Mohamed, Vladimir Yu. Startsev, Chema Drira, Omar Hamdy, Miada Mohamed Fahmi Elmetwaly, Said Nabil, Shamma Alshehhi, Gamil Othman, Hamoud H. Y. Al-Hussaini, Ahmed Zuhair Abdulhameed Alsammarraie, Arooj Abid, Nada M. Kassem, Sami El Khatib, Souheil Hallit, Diana Malaeb, Hassan Hosseini
